Addex Therapeutics Ltd Total Liabilities
Addex Therapeutics Ltd total liabilities. Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) has total liabilities worth $1.47 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ADXN asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Addex Therapeutics Ltd (2006–2025)
Total liabilities of Addex Therapeutics Ltd from 2006 to 2025. This chart illustrates how Addex Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Addex Therapeutics Ltd (ADXN) long-term investment share to see how much of total assets are deployed in long-term investments.
Addex Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Addex Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chijet Motor Company, Inc. Ordinary Shares
NASDAQ:CJET
|
USA | $657.20 Million |
|
Datasea Inc
NASDAQ:DTSS
|
USA | $7.52 Million |
|
Groupe JAJ
PA:GJAJ
|
France | €26.76 Million |
|
ASTROTECH CORP.
F:SP5
|
Germany | €4.18 Million |
|
JLT Mobile Computers AB (publ)
ST:JLT
|
Sweden | Skr33.50 Million |
|
Pelangi Indah Canindo Tbk
JK:PICO
|
Indonesia | Rp478.62 Billion |
|
Cash.Medien AG
HM:MF8
|
Germany | €861.26K |
Liability Composition Analysis (2006–2025)
This chart breaks down Addex Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Addex Therapeutics Ltd.
Liquidity & Leverage Metrics
Addex Therapeutics Ltd Total Liabilities Ratios Explained
Addex Therapeutics Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.97 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.45 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Addex Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Addex Therapeutics Ltd (2006–2025)
The table below shows the annual total liabilities of Addex Therapeutics Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.60 Million | +59.77% |
| 2024-12-31 | $1.00 Million | -71.37% |
| 2023-12-31 | $3.50 Million | +3.78% |
| 2022-12-31 | $3.37 Million | -39.95% |
| 2021-12-31 | $5.61 Million | +0.69% |
| 2020-12-31 | $5.57 Million | -25.76% |
| 2019-12-31 | $7.50 Million | +152.42% |
| 2018-12-31 | $2.97 Million | +72.79% |
| 2017-12-31 | $1.72 Million | +17.50% |
| 2016-12-31 | $1.46 Million | +19.49% |
| 2015-12-31 | $1.23 Million | -25.89% |
| 2014-12-31 | $1.65 Million | -42.06% |
| 2013-12-31 | $2.85 Million | -47.59% |
| 2012-12-31 | $5.44 Million | -44.33% |
| 2011-12-31 | $9.78 Million | -0.91% |
| 2010-12-31 | $9.87 Million | -10.05% |
| 2009-12-31 | $10.97 Million | -17.73% |
| 2008-12-31 | $13.34 Million | +43.92% |
| 2007-12-31 | $9.27 Million | +127.45% |
| 2006-12-31 | $4.07 Million | -- |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-in… Read more